OS Therapies sets up subsidiary to seek ADC joint ventures with US, China peers
As OS Therapies prepares to take its bacteria-based cancer asset to the FDA for approval, the biotech has been reaching out to peers in the U.S. and China to potentially spin off its “tunable” antibody drug conjugate tech.
As OS Therapies prepares to take its bacteria-based cancer asset to the FDA for approval, the biotech has been reaching out to peers in the U.S. and China to potentially spin off its “tunable” antibody drug conjugate tech.
